{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T21:41:06Z","timestamp":1777066866989,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ad.2024.12.027","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:48:01Z","timestamp":1747914481000},"page":"945-958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Efficacy Profile of Anti-IL17 Treatments in Hidradenitis Suppurativa: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials"],"prefix":"10.1016","volume":"116","author":[{"given":"O.","family":"Al-wattar-Ceballos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mart\u00ednez-Montalvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Carmona-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.12.027_bib0125","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.027_bib0130","first-page":"868","article-title":"S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa \u2013 short version","volume":"22","author":"Zouboulis","year":"2024","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2024.12.027_bib0135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/jid.2012.255","article-title":"Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota","volume":"133","author":"Vazquez","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2024.12.027_bib0140","article-title":"Hidradenitis supurativa","author":"Gonz\u00e1lez-L\u00f3pez","year":"2023","journal-title":"Med Cl\u00edn"},{"key":"10.1016\/j.ad.2024.12.027_bib0145","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/ijdvl.IJDVL_69_18","article-title":"Hidradenitis suppurativa: a systematic review and meta-analysis of therapeutic interventions","volume":"85","author":"Tchero","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2024.12.027_bib0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ad.2023.12.001","article-title":"Topical and intralesional therapies for hidradenitis suppurativa: a systematic literature review","volume":"115","author":"Pascual","year":"2024","journal-title":"Actas Dermo-Sifiliogr"},{"key":"10.1016\/j.ad.2024.12.027_bib0155","doi-asserted-by":"crossref","first-page":"e26190","DOI":"10.1097\/MD.0000000000026190","article-title":"Efficacy and safety of adalimumab in hidradenitis suppurativa: a systematic review and meta-analysis of randomized controlled trials","volume":"100","author":"Lu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ad.2024.12.027_bib0160","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.3390\/pharmaceutics15102450","article-title":"IL-17 inhibition: a valid therapeutic strategy in the management of hidradenitis suppurativa","volume":"15","author":"Malvaso","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ad.2024.12.027_bib0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/12034754211035667","article-title":"Treatment outcomes of IL-17 inhibitors in hidradenitis suppurativa: a systematic review","volume":"26","author":"Kashetsky","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2024.12.027_bib0170","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.12.027_bib0175","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2024.12.027_bib0180","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2024.12.027_bib0185","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ad.2024.12.027_bib0190","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.12.027_bib0195","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.ad.2024.12.027_bib0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ad.2024.12.027_bib0205","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/exd.14619","article-title":"IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study","volume":"31","author":"Kimball","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ad.2024.12.027_bib0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa","volume":"201","author":"Fletcher","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ad.2024.12.027_bib0215","first-page":"1","article-title":"Comparative efficacy and therapeutic positioning of biologics in hidradenitis suppurativa: a systematic review with network meta-analysis of randomised trials","author":"Husein-ElAhmed","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2024.12.027_bib0220","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ad.2024.12.027_bib0225","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.cell.2019.01.041","article-title":"Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans","volume":"176","author":"Bacher","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ad.2024.12.027_bib0230","doi-asserted-by":"crossref","first-page":"2442603","DOI":"10.1155\/2022\/2442603","article-title":"Risk of Candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: a systematic review and meta-analysis of randomized controlled trials","volume":"2022","author":"Feng","year":"2022","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ad.2024.12.027_bib0235","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2024.12.027_bib0240","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/ijd.16885","article-title":"Risk of infection in patients with hidradenitis suppurativa on biologics OR, other immunomodulators: a systematic review and meta-analysis","volume":"63","author":"Lazaridou","year":"2024","journal-title":"Int J Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102500362X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102500362X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:27:40Z","timestamp":1759336060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000173102500362X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S000173102500362X"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.12.027","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy Profile of Anti-IL17 Treatments in Hidradenitis Suppurativa: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}